<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>MPA Search: case notes and guides</title>
    <link>https://mpa-search.com/resources</link>
    <atom:link href="https://mpa-search.com/rss.xml" rel="self" type="application/rss+xml" />
    <description>Plain, sourced case notes and guides on pharmaceutical patents, SPCs, licences, prices and shortages in the UK and Europe.</description>
    <language>en-gb</language>
    <lastBuildDate>Fri, 20 Nov 2026 00:00:00 GMT</lastBuildDate>
    <item>
      <title>Bortezomib (Velcade): damages for generic launches, after the patents have expired</title>
      <link>https://mpa-search.com/resources/case-notes/bortezomib-velcade-damages-germany-france-2026</link>
      <guid isPermaLink="true">https://mpa-search.com/resources/case-notes/bortezomib-velcade-damages-germany-france-2026</guid>
      <pubDate>Fri, 20 Nov 2026 00:00:00 GMT</pubDate>
      <category>Case notes</category>
      <description>Velcade generics launched before the formulation patents expired in 2022. Düsseldorf refused Millennium's damages claims in 2026; Paris let them proceed.</description>
    </item>
    <item>
      <title>Dana-Farber's PD-L1 SPCs: can you extend your patent with someone else's antibody?</title>
      <link>https://mpa-search.com/resources/case-notes/anti-pd-l1-antibody-spcs-dana-farber-2025</link>
      <guid isPermaLink="true">https://mpa-search.com/resources/case-notes/anti-pd-l1-antibody-spcs-dana-farber-2025</guid>
      <pubDate>Fri, 20 Nov 2026 00:00:00 GMT</pubDate>
      <category>Case notes</category>
      <description>Dana-Farber sought SPCs on three PD-L1 antibodies its licensees developed. The Netherlands refused all three in 2025; France split. Why, and what it means.</description>
    </item>
    <item>
      <title>Divisional patents: why revoking one patent rarely clears a product</title>
      <link>https://mpa-search.com/resources/explainers/divisional-applications-and-the-divisional-game</link>
      <guid isPermaLink="true">https://mpa-search.com/resources/explainers/divisional-applications-and-the-divisional-game</guid>
      <pubDate>Fri, 20 Nov 2026 00:00:00 GMT</pubDate>
      <category>Explainers</category>
      <description>How divisional patent applications keep a medicine protected after a parent patent falls, the 2024–2026 rulings on the divisional game, and what to check.</description>
    </item>
    <item>
      <title>Rifaximin for hepatic encephalopathy: eight opponents clear a use patent at the EPO</title>
      <link>https://mpa-search.com/resources/case-notes/rifaximin-hepatic-encephalopathy-epo-2025</link>
      <guid isPermaLink="true">https://mpa-search.com/resources/case-notes/rifaximin-hepatic-encephalopathy-epo-2025</guid>
      <pubDate>Fri, 20 Nov 2026 00:00:00 GMT</pubDate>
      <category>Case notes</category>
      <description>The EPO revoked Salix's rifaximin hepatic encephalopathy use patent in 2025 after eight oppositions. What it opens for generics and what still stands.</description>
    </item>
    <item>
      <title>Semaglutide nasal spray: the Dutch pharmacy exemption does not cover compounding at scale</title>
      <link>https://mpa-search.com/resources/case-notes/semaglutide-nasal-spray-pharmacy-exemption-netherlands-2026</link>
      <guid isPermaLink="true">https://mpa-search.com/resources/case-notes/semaglutide-nasal-spray-pharmacy-exemption-netherlands-2026</guid>
      <pubDate>Fri, 20 Nov 2026 00:00:00 GMT</pubDate>
      <category>Case notes</category>
      <description>A Dutch court held in August 2026 that compounding semaglutide nasal spray at scale is not covered by the pharmacy exemption while the SPC runs.</description>
    </item>
    <item>
      <title>Ustekinumab (Stelara): a use patent that is valid in the Netherlands and revoked in the UK</title>
      <link>https://mpa-search.com/resources/case-notes/ustekinumab-stelara-ulcerative-colitis-patent-2025</link>
      <guid isPermaLink="true">https://mpa-search.com/resources/case-notes/ustekinumab-stelara-ulcerative-colitis-patent-2025</guid>
      <pubDate>Fri, 20 Nov 2026 00:00:00 GMT</pubDate>
      <category>Case notes</category>
      <description>Janssen's ustekinumab ulcerative colitis patent was upheld in the Netherlands in 2025 but revoked in the UK and Switzerland. What it means for biosimilars.</description>
    </item>
    <item>
      <title>GSK v Pfizer and BioNTech (Comirnaty): a UPC injunction for 35 countries that waits for a licence</title>
      <link>https://mpa-search.com/resources/case-notes/gsk-v-pfizer-biontech-comirnaty-upc-2026</link>
      <guid isPermaLink="true">https://mpa-search.com/resources/case-notes/gsk-v-pfizer-biontech-comirnaty-upc-2026</guid>
      <pubDate>Sat, 14 Nov 2026 00:00:00 GMT</pubDate>
      <category>Case notes</category>
      <description>The UPC held Comirnaty infringes GSK's lipid patent and granted an injunction reaching Spain, Poland, Switzerland and Turkey, deferred pending a licence.</description>
    </item>
    <item>
      <title>Long-arm jurisdiction: when one court's patent injunction covers other countries</title>
      <link>https://mpa-search.com/resources/explainers/long-arm-jurisdiction-cross-border-patent-injunctions</link>
      <guid isPermaLink="true">https://mpa-search.com/resources/explainers/long-arm-jurisdiction-cross-border-patent-injunctions</guid>
      <pubDate>Sat, 14 Nov 2026 00:00:00 GMT</pubDate>
      <category>Explainers</category>
      <description>How one court can now enjoin a medicine across Europe, including Spain, Poland, Switzerland and the UK: the BSH v Electrolux rule and the cases applying it.</description>
    </item>
    <item>
      <title>Why patent disputes end in settlements, and what that does to launch dates</title>
      <link>https://mpa-search.com/resources/explainers/patent-settlements-and-launch-dates</link>
      <guid isPermaLink="true">https://mpa-search.com/resources/explainers/patent-settlements-and-launch-dates</guid>
      <pubDate>Sat, 14 Nov 2026 00:00:00 GMT</pubDate>
      <category>Explainers</category>
      <description>Most pharma patent disputes settle, and the settlement sets the launch date. Why they settle, the pay-for-delay limit, and how to spot one from public signs.</description>
    </item>
    <item>
      <title>Vedolizumab: four biosimilar developers ask the Patents Court to clear the way for Entyvio biosimilars</title>
      <link>https://mpa-search.com/resources/case-notes/vedolizumab-entyvio-uk-clear-the-way-2026</link>
      <guid isPermaLink="true">https://mpa-search.com/resources/case-notes/vedolizumab-entyvio-uk-clear-the-way-2026</guid>
      <pubDate>Fri, 06 Nov 2026 00:00:00 GMT</pubDate>
      <category>Case notes</category>
      <description>Fresenius Kabi, Advanz, Accord and Samsung Bioepis v Millennium (Takeda): the UK vedolizumab clear-the-way action, 4 patents, trial from 6 April 2027.</description>
    </item>
    <item>
      <title>De Peijper: the regulator may not make a parallel importer resupply a dossier it already holds</title>
      <link>https://mpa-search.com/resources/case-notes/de-peijper-parallel-imports-no-second-dossier-cjeu-1976</link>
      <guid isPermaLink="true">https://mpa-search.com/resources/case-notes/de-peijper-parallel-imports-no-second-dossier-cjeu-1976</guid>
      <pubDate>Thu, 05 Nov 2026 00:00:00 GMT</pubDate>
      <category>Case notes</category>
      <description>De Peijper (1976): the CJEU held a regulator may not make a parallel importer resupply particulars it already holds. The root of every parallel import scheme.</description>
    </item>
    <item>
      <title>Kohlpharma: a parallel import cannot be refused solely because there is no common origin</title>
      <link>https://mpa-search.com/resources/case-notes/kohlpharma-jumex-movergan-common-origin-not-required-cjeu-2004</link>
      <guid isPermaLink="true">https://mpa-search.com/resources/case-notes/kohlpharma-jumex-movergan-common-origin-not-required-cjeu-2004</guid>
      <pubDate>Thu, 05 Nov 2026 00:00:00 GMT</pubDate>
      <category>Case notes</category>
      <description>Kohlpharma (2004): a parallel import cannot be refused solely for lack of a common origin, the CJEU held. The basis of standard and complex UK applications.</description>
    </item>
    <item>
      <title>Rhône-Poulenc Rorer: a parallel import with different excipients can still use the simplified route</title>
      <link>https://mpa-search.com/resources/case-notes/rhone-poulenc-rorer-zimovane-parallel-import-excipients-cjeu-1999</link>
      <guid isPermaLink="true">https://mpa-search.com/resources/case-notes/rhone-poulenc-rorer-zimovane-parallel-import-excipients-cjeu-1999</guid>
      <pubDate>Thu, 05 Nov 2026 00:00:00 GMT</pubDate>
      <category>Case notes</category>
      <description>Rhône-Poulenc Rorer (1999): different excipients and process do not bar a parallel import licence if the regulator can verify safety, the CJEU held.</description>
    </item>
    <item>
      <title>Smith &amp; Nephew and Primecrown: products made under licence from the same licensor have a common origin</title>
      <link>https://mpa-search.com/resources/case-notes/smith-nephew-primecrown-ditropan-common-origin-cjeu-1996</link>
      <guid isPermaLink="true">https://mpa-search.com/resources/case-notes/smith-nephew-primecrown-ditropan-common-origin-cjeu-1996</guid>
      <pubDate>Thu, 05 Nov 2026 00:00:00 GMT</pubDate>
      <category>Case notes</category>
      <description>Smith &amp; Nephew and Primecrown (1996): products licensed by the same licensor share a common origin, and the same-formulation test for UK parallel imports.</description>
    </item>
    <item>
      <title>UK parallel import licences: simple, standard and complex applications, what each needs, and the law behind them</title>
      <link>https://mpa-search.com/resources/explainers/uk-parallel-import-licence-applications-simple-standard-complex</link>
      <guid isPermaLink="true">https://mpa-search.com/resources/explainers/uk-parallel-import-licence-applications-simple-standard-complex</guid>
      <pubDate>Thu, 05 Nov 2026 00:00:00 GMT</pubDate>
      <category>Explainers</category>
      <description>Simple, standard and complex UK parallel import licence applications: what each covers, what every application needs, the fees, and the law behind them.</description>
    </item>
    <item>
      <title>Astellas v Polpharma: can a third party sell the patented active ingredient to a generic company for its trials?</title>
      <link>https://mpa-search.com/resources/case-notes/solifenacin-astellas-v-polpharma-bolar-api-supply-2013</link>
      <guid isPermaLink="true">https://mpa-search.com/resources/case-notes/solifenacin-astellas-v-polpharma-bolar-api-supply-2013</guid>
      <pubDate>Wed, 04 Nov 2026 00:00:00 GMT</pubDate>
      <category>Case notes</category>
      <description>Can a supplier sell a patented API to a generic company for its trials? Poland's Supreme Court said no in Astellas v Polpharma; Europe has no answer yet.</description>
    </item>
    <item>
      <title>Delfarma: a parallel import licence cannot die automatically when the reference licence lapses</title>
      <link>https://mpa-search.com/resources/case-notes/ribomunyl-delfarma-parallel-import-licence-expiry-cjeu-2021</link>
      <guid isPermaLink="true">https://mpa-search.com/resources/case-notes/ribomunyl-delfarma-parallel-import-licence-expiry-cjeu-2021</guid>
      <pubDate>Wed, 04 Nov 2026 00:00:00 GMT</pubDate>
      <category>Case notes</category>
      <description>The CJEU held in 2021 that a parallel import licence cannot expire automatically when the reference authorisation lapses under the sunset clause.</description>
    </item>
    <item>
      <title>The Bolar exemption: what a generic may do while the patent is still running, and what it may not</title>
      <link>https://mpa-search.com/resources/explainers/bolar-exemption-europe</link>
      <guid isPermaLink="true">https://mpa-search.com/resources/explainers/bolar-exemption-europe</guid>
      <pubDate>Wed, 04 Nov 2026 00:00:00 GMT</pubDate>
      <category>Explainers</category>
      <description>What the Bolar exemption lets a generic do before the patent or SPC expires, what it does not cover, and how the EU pharmaceutical package widens it.</description>
    </item>
    <item>
      <title>The sunset clause: how a marketing authorisation dies of disuse, and when the three years start</title>
      <link>https://mpa-search.com/resources/explainers/sunset-clause-marketing-authorisations</link>
      <guid isPermaLink="true">https://mpa-search.com/resources/explainers/sunset-clause-marketing-authorisations</guid>
      <pubDate>Wed, 04 Nov 2026 00:00:00 GMT</pubDate>
      <category>Explainers</category>
      <description>How the sunset clause lapses an unused marketing authorisation after three years, when the clock starts for a generic, and what replaces it in the EU reform.</description>
    </item>
    <item>
      <title>Bristol-Myers Squibb v Paranova: the five conditions every repackaged parallel import still has to meet</title>
      <link>https://mpa-search.com/resources/case-notes/bms-v-paranova-repackaging-conditions-cjeu-1996</link>
      <guid isPermaLink="true">https://mpa-search.com/resources/case-notes/bms-v-paranova-repackaging-conditions-cjeu-1996</guid>
      <pubDate>Mon, 02 Nov 2026 00:00:00 GMT</pubDate>
      <category>Case notes</category>
      <description>The five BMS v Paranova conditions from 1996 that every repackaged parallel import must still meet, explained for parallel traders and importers.</description>
    </item>
    <item>
      <title>Enbrel (etanercept) from the accession states: the Specific Mechanism reaches SPCs and paediatric extensions too</title>
      <link>https://mpa-search.com/resources/case-notes/etanercept-enbrel-specific-mechanism-cjeu-2018</link>
      <guid isPermaLink="true">https://mpa-search.com/resources/case-notes/etanercept-enbrel-specific-mechanism-cjeu-2018</guid>
      <pubDate>Mon, 02 Nov 2026 00:00:00 GMT</pubDate>
      <category>Case notes</category>
      <description>The CJEU ruled in 2018 that the Specific Mechanism protects SPCs and paediatric extensions against Enbrel imports from the newer member states.</description>
    </item>
    <item>
      <title>Full, generic, hybrid, biosimilar, well-established use, fixed combination, informed consent: the legal basis of a marketing authorisation and what it tells you</title>
      <link>https://mpa-search.com/resources/explainers/legal-bases-of-a-marketing-authorisation</link>
      <guid isPermaLink="true">https://mpa-search.com/resources/explainers/legal-bases-of-a-marketing-authorisation</guid>
      <pubDate>Mon, 02 Nov 2026 00:00:00 GMT</pubDate>
      <category>Explainers</category>
      <description>The legal basis of a marketing authorisation, from full dossier to generic, hybrid and biosimilar, and what each tells you about exclusivity.</description>
    </item>
    <item>
      <title>Singulair (montelukast) from Poland: the Specific Mechanism's one-month notice, and what silence costs</title>
      <link>https://mpa-search.com/resources/case-notes/montelukast-singulair-specific-mechanism-cjeu-2015</link>
      <guid isPermaLink="true">https://mpa-search.com/resources/case-notes/montelukast-singulair-specific-mechanism-cjeu-2015</guid>
      <pubDate>Mon, 02 Nov 2026 00:00:00 GMT</pubDate>
      <category>Case notes</category>
      <description>The CJEU's 2015 Singulair ruling on the Specific Mechanism: the one-month notice, who must receive it, and what a patent holder's silence costs.</description>
    </item>
    <item>
      <title>The Specific Mechanism: when a patent could stop a parallel import from the newer member states</title>
      <link>https://mpa-search.com/resources/explainers/specific-mechanism-parallel-imports-accession-states</link>
      <guid isPermaLink="true">https://mpa-search.com/resources/explainers/specific-mechanism-parallel-imports-accession-states</guid>
      <pubDate>Mon, 02 Nov 2026 00:00:00 GMT</pubDate>
      <category>Explainers</category>
      <description>The Specific Mechanism lets a patent holder stop parallel imports from EU states that joined from 2004. What it says, the key dates and the CJEU rulings.</description>
    </item>
    <item>
      <title>Aumolertinib (Aumseqa): an EU authorisation revoked for leaning on protected data</title>
      <link>https://mpa-search.com/resources/case-notes/aumolertinib-aumseqa-eu-revocation-data-protection-2026</link>
      <guid isPermaLink="true">https://mpa-search.com/resources/case-notes/aumolertinib-aumseqa-eu-revocation-data-protection-2026</guid>
      <pubDate>Sat, 31 Oct 2026 00:00:00 GMT</pubDate>
      <category>Case notes</category>
      <description>The European Commission revoked the EU authorisation for aumolertinib in 2026 because the application relied on AstraZeneca data still under protection.</description>
    </item>
    <item>
      <title>Semaglutide at the UPC: Milan says it can stop the &quot;divisional game&quot;</title>
      <link>https://mpa-search.com/resources/case-notes/semaglutide-divisional-game-upc-milan-2026</link>
      <guid isPermaLink="true">https://mpa-search.com/resources/case-notes/semaglutide-divisional-game-upc-milan-2026</guid>
      <pubDate>Sat, 31 Oct 2026 00:00:00 GMT</pubDate>
      <category>Case notes</category>
      <description>The UPC Milan central division held in 2026 that it can stop the 'divisional game' in Sandoz v Novo Nordisk over semaglutide. What it changes for launches.</description>
    </item>
    <item>
      <title>How strong is each kind of pharmaceutical patent? A field guide, with the biologics twist</title>
      <link>https://mpa-search.com/resources/explainers/how-strong-is-each-kind-of-patent</link>
      <guid isPermaLink="true">https://mpa-search.com/resources/explainers/how-strong-is-each-kind-of-patent</guid>
      <pubDate>Mon, 26 Oct 2026 00:00:00 GMT</pubDate>
      <category>Explainers</category>
      <description>Which pharmaceutical patents usually hold and which usually fall: compound, process, formulation, use, combination and device, with the biologics twist.</description>
    </item>
    <item>
      <title>Skinny labels: why carving out the patented indication reduces the risk but does not remove it</title>
      <link>https://mpa-search.com/resources/case-notes/skinny-labels-carve-outs-pregabalin-and-after</link>
      <guid isPermaLink="true">https://mpa-search.com/resources/case-notes/skinny-labels-carve-outs-pregabalin-and-after</guid>
      <pubDate>Mon, 26 Oct 2026 00:00:00 GMT</pubDate>
      <category>Case notes</category>
      <description>Why a skinny label reduces but never removes patent risk: the UK pregabalin case, Dutch tenders, German rebate contracts and the UPC's 2025 test.</description>
    </item>
    <item>
      <title>The A to Z: patent, SPC, licensing, regulatory, trade and pricing terms, defined plainly</title>
      <link>https://mpa-search.com/resources/glossary/a-to-z-of-terms</link>
      <guid isPermaLink="true">https://mpa-search.com/resources/glossary/a-to-z-of-terms</guid>
      <pubDate>Mon, 26 Oct 2026 00:00:00 GMT</pubDate>
      <category>Glossary</category>
      <description>Plain definitions of patent, SPC, regulatory, licensing, parallel trade and pricing terms, from added matter to the Windsor Framework, with links.</description>
    </item>
    <item>
      <title>'Launch or lose protection' and the parallel-trade safeguards in the EU pharmaceutical package</title>
      <link>https://mpa-search.com/resources/regulatory-changes/eu-pharma-package-launch-or-lose-parallel-trade</link>
      <guid isPermaLink="true">https://mpa-search.com/resources/regulatory-changes/eu-pharma-package-launch-or-lose-parallel-trade</guid>
      <pubDate>Sun, 25 Oct 2026 00:00:00 GMT</pubDate>
      <category>Regulatory changes</category>
      <description>Under the EU package a product not launched in a member state within three years of a request loses protection there. Plus the new parallel-trade rules.</description>
    </item>
    <item>
      <title>Aflibercept (Eylea) biosimilars: on sale in the UK from November 2025, enjoined in Germany until the spring</title>
      <link>https://mpa-search.com/resources/case-notes/aflibercept-eylea-europe-split-2026</link>
      <guid isPermaLink="true">https://mpa-search.com/resources/case-notes/aflibercept-eylea-europe-split-2026</guid>
      <pubDate>Sun, 25 Oct 2026 00:00:00 GMT</pubDate>
      <category>Case notes</category>
      <description>A formulation patent split Europe for Eylea (aflibercept) biosimilars: on sale in the UK from November 2025, enjoined in Germany until spring 2026.</description>
    </item>
    <item>
      <title>Biosimilar entry in Europe, autumn 2026: what launched, what settled, what is blocked</title>
      <link>https://mpa-search.com/resources/watch-list/biosimilar-entry-europe-autumn-2026</link>
      <guid isPermaLink="true">https://mpa-search.com/resources/watch-list/biosimilar-entry-europe-autumn-2026</guid>
      <pubDate>Sun, 25 Oct 2026 00:00:00 GMT</pubDate>
      <category>Watch list</category>
      <description>Which biosimilars launched, settled or stayed blocked in the UK and EU this past year, from aflibercept to vedolizumab, and the next dates to watch.</description>
    </item>
    <item>
      <title>Cabazitaxel (Jevtana): the UPC revokes a use patent the EPO had just upheld</title>
      <link>https://mpa-search.com/resources/case-notes/cabazitaxel-jevtana-upc-2025</link>
      <guid isPermaLink="true">https://mpa-search.com/resources/case-notes/cabazitaxel-jevtana-upc-2025</guid>
      <pubDate>Sun, 25 Oct 2026 00:00:00 GMT</pubDate>
      <category>Case notes</category>
      <description>The UPC revoked Sanofi's cabazitaxel (Jevtana) use patent in nine countries in December 2025, months after the EPO upheld it. What it means for generics.</description>
    </item>
    <item>
      <title>Dabigatran: when the patentee blocking your generic is another generic company</title>
      <link>https://mpa-search.com/resources/case-notes/dabigatran-generic-v-generic-munich-2026</link>
      <guid isPermaLink="true">https://mpa-search.com/resources/case-notes/dabigatran-generic-v-generic-munich-2026</guid>
      <pubDate>Sun, 25 Oct 2026 00:00:00 GMT</pubDate>
      <category>Case notes</category>
      <description>Munich enjoined Accord's generic dabigatran in 2026 on another generic company's formulation patent. A freedom-to-operate risk that reviews often miss.</description>
    </item>
    <item>
      <title>Empagliflozin (Jardiance): the UK holds the ring while the SGLT2 question is tried again</title>
      <link>https://mpa-search.com/resources/case-notes/empagliflozin-jardiance-uk-2025</link>
      <guid isPermaLink="true">https://mpa-search.com/resources/case-notes/empagliflozin-jardiance-uk-2025</guid>
      <pubDate>Sun, 25 Oct 2026 00:00:00 GMT</pubDate>
      <category>Case notes</category>
      <description>An interim injunction keeps Dr Reddy's generic empagliflozin (Jardiance) off the UK market until trial. Where the UK SPC to 2029 and the EPO case stand.</description>
    </item>
    <item>
      <title>EU–US pharmaceutical tariffs and 'most-favoured-nation' pricing: what it does to European prices and launches</title>
      <link>https://mpa-search.com/resources/regulatory-changes/eu-us-tariffs-mfn-pricing-2026</link>
      <guid isPermaLink="true">https://mpa-search.com/resources/regulatory-changes/eu-us-tariffs-mfn-pricing-2026</guid>
      <pubDate>Sun, 25 Oct 2026 00:00:00 GMT</pubDate>
      <category>Regulatory changes</category>
      <description>How the 15% EU–US pharma tariff, the Section 232 proclamation and most-favoured-nation pricing deals reach European list prices, launches and parallel trade.</description>
    </item>
    <item>
      <title>Export restrictions on medicines, country by country: the position in autumn 2026</title>
      <link>https://mpa-search.com/resources/regulatory-changes/export-restrictions-europe-autumn-2026</link>
      <guid isPermaLink="true">https://mpa-search.com/resources/regulatory-changes/export-restrictions-europe-autumn-2026</guid>
      <pubDate>Sun, 25 Oct 2026 00:00:00 GMT</pubDate>
      <category>Regulatory changes</category>
      <description>Where a parallel exporter needs a licence or notice, or cannot ship at all: Greece, Portugal, Belgium, Poland, Italy, Slovakia and Czechia, autumn 2026.</description>
    </item>
    <item>
      <title>Fampridine (Fampyra): the UPC's first SPC case, and when the urgency clock starts</title>
      <link>https://mpa-search.com/resources/case-notes/fampridine-fampyra-upc-2026</link>
      <guid isPermaLink="true">https://mpa-search.com/resources/case-notes/fampridine-fampyra-upc-2026</guid>
      <pubDate>Sun, 25 Oct 2026 00:00:00 GMT</pubDate>
      <category>Case notes</category>
      <description>The UPC's first SPC case: Viatris's generic fampridine enjoined in France in 2026 after eleven months on sale, and when the urgency clock starts.</description>
    </item>
    <item>
      <title>Fixed-dose combinations: three live questions on exclusivity for a combination of known actives</title>
      <link>https://mpa-search.com/resources/case-notes/fixed-dose-combinations-spc-2026</link>
      <guid isPermaLink="true">https://mpa-search.com/resources/case-notes/fixed-dose-combinations-spc-2026</guid>
      <pubDate>Sun, 25 Oct 2026 00:00:00 GMT</pubDate>
      <category>Case notes</category>
      <description>Three live questions on exclusivity for fixed-dose combinations of known actives: the Paris dapagliflozin refusal, daratumumab, and a Dutch referral.</description>
    </item>
    <item>
      <title>France's social security financing law for 2026: generics out of the clawback, discount caps, and biosimilar substitution levers</title>
      <link>https://mpa-search.com/resources/regulatory-changes/france-lfss-2026-generics-biosimilars</link>
      <guid isPermaLink="true">https://mpa-search.com/resources/regulatory-changes/france-lfss-2026-generics-biosimilars</guid>
      <pubDate>Sun, 25 Oct 2026 00:00:00 GMT</pubDate>
      <category>Regulatory changes</category>
      <description>France's 2026 social security law takes generics and biosimilars out of the clawback, caps pharmacy discounts and adds levers for biosimilar substitution.</description>
    </item>
  </channel>
</rss>
